Santa Monica, CA24 Active Studies

Ankylosing Spondylitis Clinical Trials in Santa Monica, CA

Find 24 actively recruiting ankylosing spondylitis clinical trials in Santa Monica, CA. Connect with local research sites and explore new treatment options.

24
Active Trials
22
Sponsors
6,108
Enrolling

Recruiting Ankylosing Spondylitis Studies in Santa Monica

RecruitingSanta Monica, CANCT06764875

A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

This is a Phase â…¢, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) c...

840 participants
AstraZeneca
View Study Details
RecruitingSanta Monica, CANCT05232916

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk f...

750 participants
Greenwich LifeSciences, Inc.
View Study Details
RecruitingSanta Monica, CANCT04638647

Secukinumab Open Label Roll-over Extension Protocol

The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment w...

715 participants
Novartis Pharmaceuticals
View Study Details
RecruitingSanta Monica, CANCT04379596

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemoth...

413 participants
AstraZeneca
View Study Details
RecruitingSanta Monica, CANCT06797635

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The ma...

372 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingSanta Monica, CANCT04802759

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments be...

316 participants
Hoffmann-La Roche
View Study Details
RecruitingSanta Monica, CANCT06812325

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED)....

284 participants
Viridian Therapeutics, Inc.
View Study Details
RecruitingSanta Monica, CANCT04851613

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Study LAE205INT3101 is a Phase Ib/III study to evaluate the efficacy and safety of the combination therapy with afuresertib plus fulvestrant (afuresertib/placebo plus fulvestrant in Phase III) in pati...

256 participants
Laekna Limited
View Study Details
RecruitingSanta Monica, CANCT06572228

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breat...

250 participants
Regeneron Pharmaceuticals
View Study Details
RecruitingSanta Monica, CANCT05710328

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG) positron emission tomography/computed tomography (PET/CT) works in predicting response to standard of care che...

235 participants
ECOG-ACRIN Cancer Research Group
View Study Details
RecruitingSanta Monica, CANCT06628310

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is gi...

180 participants
AbbVie
View Study Details
RecruitingSanta Monica, CANCT06157892

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spre...

172 participants
Seagen, a wholly owned subsidiary of Pfizer
View Study Details
RecruitingSanta Monica, CANCT05708352

A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment

This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Di...

170 participants
Cedars-Sinai Medical Center
View Study Details
RecruitingSanta Monica, CANCT06038578

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with ...

146 participants
Toray Industries, Inc
View Study Details
RecruitingSanta Monica, CANCT06340451

Study to Assess the Efficacy and Safety of Iovera®° System in Subjects With Upper Extremity Spasticity

This multicenter, randomized, double-blind, sham-controlled study is designed to evaluate the efficacy and safety of the iovera° system in subjects with upper extremity spasticity. A total of approxim...

132 participants
Pacira Pharmaceuticals, Inc
View Study Details
RecruitingSanta Monica, CANCT06596694

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the bod...

130 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingSanta Monica, CANCT06590857

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs....

124 participants
RayzeBio, Inc.
View Study Details
RecruitingSanta Monica, CANCT04759664

LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

The study evaluates the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 4 weeks, compared to placebo, in metastatic colorectal cancer (mCRC) patients who developed ...

117 participants
Lutris Pharma Ltd.
View Study Details
RecruitingSanta Monica, CANCT06449222

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeuti...

100 participants
BioNTech SE
View Study Details
RecruitingSanta Monica, CANCT04042844

A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

This is a double-blind, controlled, randomized study with blinded assessments using a single dose. Subjects that have a current diagnosis of chronic lumbar disc disease and meet eligibility criteria w...

99 participants
BioRestorative Therapies
View Study Details
RecruitingSanta Monica, CANCT06506916

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderat...

90 participants
UCB Biopharma SRL
View Study Details
RecruitingSanta Monica, CANCT03862430

A Study of NanO2â„¢ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM

This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase...

87 participants
NuvOx LLC
View Study Details
RecruitingSanta Monica, CANCT07090330

ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis

This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants wit...

80 participants
Oruka Therapeutics, Inc.
View Study Details
RecruitingSanta Monica, CANCT06088199

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis....

50 participants
Amgen
View Study Details

About Ankylosing Spondylitis Clinical Trials in Santa Monica

Ankylosing spondylitis is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing pain, stiffness, and potentially spinal fusion. It typically begins in early adulthood. Treatment includes NSAIDs, biologics (TNF and IL-17 inhibitors), and physical therapy.

There are currently 24 ankylosing spondylitis clinical trials recruiting participants in Santa Monica, CA. These studies are seeking a combined 6,108 participants. Research is being sponsored by AstraZeneca, Greenwich LifeSciences, Inc., Novartis Pharmaceuticals and 19 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Ankylosing Spondylitis Clinical Trials in Santa Monica — FAQ

Are there ankylosing spondylitis clinical trials in Santa Monica?

Yes, there are 24 ankylosing spondylitis clinical trials currently recruiting in Santa Monica, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Santa Monica?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Santa Monica research site will contact you about next steps.

Are clinical trials in Santa Monica free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Santa Monica studies also compensate for your time and travel.

What ankylosing spondylitis treatments are being tested?

The 24 active trials in Santa Monica are testing new therapies including novel drugs, biologics, and treatment approaches for ankylosing spondylitis.

Data updated March 2, 2026 from ClinicalTrials.gov